"The
Report PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and
Market Analysis to 2025 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
Neisseria
meningitidis is a Gram-negative, encapsulated diplococcal bacterium
and is the causative agent for invasive meningococcal disease.
Although relatively rare around the globe, invasive meningococcal
disease is widely feared because of its high mortality rate even in
otherwise healthy individuals. The onset of invasive meningococcal
disease typically begins within three to seven days of infection, but
can occur as early as one day after infection. If left untreated,
meningococcal disease progresses rapidly. Even with appropriate
treatment, up to 10% of all cases still result in death within 24 to
48 hours of symptom onset. This rapid onset and progression of the
disease emphasizes the need for a prophylactic approach by
vaccination.
Pharmaceutical
companies have developed vaccines addressing the most urgent medical
needs based on clinical efficacy and epidemiology. The resulting
vaccines can be divided into three categories, although other and
finer segmentations can be made. These three categories include
monovalent vaccines targeting serogroup C (MenC vaccines), vaccines
protecting against most serogroup B strains (MenB vaccines), and
tetravalent vaccines protecting against serogroups A, C, W, and Y
(MenACWY vaccines). While the MenB vaccines use recombinant proteins
as antigens, all other meningococcal vaccines are based on the
polysaccharide capsules of the various serogroups.
View
Report At : http://www.marketresearchreports.biz/analysis/816330
Highlights
Key
Questions Answered
-
Based on interviews with key opinion leaders (KOLs), GlobalData has
identified key unmet needs in the meningococcal vaccine marketplace.
-
What will be the effect of recent and upcoming changes in national
immunization schedules?
-
How will the new first-in-class vaccine covering all main serogroups
(MenABCWY) be received in the different markets?
-
What research and development (R&D) strategies will companies
leverage to compete in the future meningococcal vaccine marketplace?
-
Which patient population(s) are most likely to be targeted for
vaccines against serogroup B and the pentavalent MenABCWY pipeline
vaccine?
Key
Findings
-
GlobalData projects the meningococcal vaccine market in the US, 5EU,
Japan, and Brazil to grow from approximately $1.1bn in 2015 to $1.8bn
in 2025, at a compound annual growth rate (CAGR) of 5.4%. This growth
across the 8MM will primarily be driven by the introduction of
additional meningococcal vaccines into the national routine infant
and adolescent vaccination schedules in some 5EU countries. Further
growth will be the result of the launch of a pentavalent MenABCWY
vaccine during the forecast period while the commercial meningococcal
vaccine markets in Brazil and Japan will experience a decline at a
negative CAGR of 1.8% and 0.9% respectively.
-
With most countries in the 8MM using serogroup B vaccines only for
individuals at high risk of contracting meningococcal disease, the
routine application of these protein-based vaccines is seen as the
major unmet need to be addressed in the oncoming years.
-
GlobalData anticipates that opportunities will center on the
improvement of vaccine long-term efficacy whilst addressing the cost
effectiveness concerns voiced by various governmental institutions.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/816330
Scope
-
Overview of meningococcal disease, including epidemiology, etiology,
pathophysiology, regional serogroup distribution, as well current
routine meningococcal vaccine recommendations of all 8MM covered.
-
Topline meningococcal vaccine market revenue from 2015-2025. Recent
acquisitions, approvals and governmental recommendations are included
in the forecast model.
-
Key topics covered include strategic competitor assessment, market
characterization, unmet needs, R&D strategies, and clinical trial
design for the meningococcal vaccine market.
-
Pipeline analysis: comprehensive data split across different phases,
emerging novel trends under development, synopses of innovative
early-stage projects, and analysis of late-stage pipeline products.
An interactive clinical and commercial analyzer tool is available.
-
Analysis of the current and future market competition in the global
meningococcal vaccine marketplace. Insightful review of the key
industry drivers, restraints and challenges. Each trend is
independently researched to provide qualitative analysis of its
implications.
Reasons
to buy
The
report will enable you to -
-
Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline.
-
Develop business strategies by understanding the trends shaping and
driving the global meningococcal vaccine market.
-
Drive revenues by understanding the key trends, innovative products
and technologies, market segments, and companies likely to impact the
meningococcal vaccine market in the future.
-
Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analyzing the performance of various
competitors.
-
Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive
advantage.
-
Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for
consolidations, investments and strategic partnerships.
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
Table
of Contents
1
Table of Contents
1
Table of Contents 11
1.1
List of Tables 18
1.2
List of Figures 24
2
Introduction 26
2.1
Catalyst 26
2.2
Related Reports 27
2.3
Upcoming Related Reports 27
3
Disease Overview 28
3.1
Introduction 28
3.2
Etiology and Pathophysiology 29
3.2.1
Etiology 29
3.2.2
Pathophysiology 35
3.3
Symptoms 37
3.4
Prognosis 38
4
Epidemiology 39
4.1
Disease Background 39
4.2
Risk Factors and morbidities 40
4.3
Global Trends 42
4.3.1
US 43
4.3.2
5EU 44
4.3.3
Japan and Brazil 46
4.4
Forecast Methodology 47
4.4.1
Sources Used Tables 48
4.4.2
Forecast Assumptions and Methods 55
4.4.3
Sources Not Used 69
4.5
Epidemiological Forecast for IMD (2015-2025) 70
4.5.1
All IMD Combined 70
4.5.2
Laboratory-Confirmed Incident Cases of Serogroup B IMD 79
4.5.3
Laboratory-Confirmed Incident Cases of Serogroup C IMD 82
4.5.4
Laboratory-Confirmed Incident Cases of Serogroup Y IMD 84
4.5.5
Laboratory-Confirmed Incident Cases of Other Serogroup IMD 86
4.5.6
Distribution of Serogroups 88
4.5.7
US College Freshmen 90
4.6
Discussion 91
4.6.1
Epidemiological Forecast Insight 91
4.6.2
Limitations of the Analysis 93
4.6.3
Strengths of the Analysis 94
5
Disease Management 95
5.1
Meningococcal Immunization Policy 95
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment